medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2023, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2023; 43 (4)

The Effect of COVID-19 Pandemic on Distribution of Biopsy- Proven Glomerular Disease: A Single Center Experience

Toprak Z, Ersoy YE, Kayabasi H, Sit D, Gursoy F

Language: English
References: 35
Page: 219-227
PDF size: 240.28 Kb.


ABSTRACT

Introduction: This study aims to examine the patients who underwent kidney biopsies due to urinary abnormalities and/or kidney failure in our unit and whether there was a change in the distribution of glomerular diseases before and after the coronavirus disease-2019 pandemic. Materials and Methods: The patients were divided into pre-pandemic (group-1) and post-pandemic (group-2). The frequency of renal pathology results and the representative clinical syndrome were compared between groups. Results: 452 patients [median age: 48 years (IQR: 36.25- 58), 54.8% male], (group-1, n:215; 47.57%), (group-2, n:237; 52,43%)) were included in the study. Non-nephrotic proteinuria was the most common indication in both two groups. The frequency of nephrotic syndrome was significantly higher in group-1 (19.5%, p:0.007). The acute or rapidly progressive renal failure frequency was significantly higher in group-2 (p:0.021). The median 24-hour urine protein level was 1354 (IQR:521-3000) mg/ day, significantly lower in group-2 (p: 0,001). Primary glomerular disease was the most common category (42.19%), followed by secondary glomerular diseases (35.02%) and tubulointerstitial nephropathies (6.32%) in group-2. The frequency of primary glomerular disease was significantly higher in group-1 (p:0.022). Hypertensive nephrosclerosis (6.80%) was common in group-2 compared to group-1 (p:0,026). Conclusion: We did not detect an increase in the prevalence of primary glomerular disease; on the contrary, there was a decrease in the prevalence of primary glomerular disease in the post-pandemic period. The acute or rapidly progressive renal failure frequency was significantly higher in the postpandemic period. Further multicenter studies are needed to determine the effect of the COVID-19 pandemic on glomerular diseases.


REFERENCES

  1. Who.int [Internet]. Organization WH. World HealthOrganization. Director-General’s remarks at themedia briefing on 2019-nCoV on 11 February 2020.Available from: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-mediabriefing-on-2019-ncov-on-11-february-2020

  2. OurWorldInData.org [Internet]. Ritchie H, MathieuE, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19).2020. Available from: https://ourworldindata.org/coronavirus

  3. OurWorldInData.org [Internet]. Ritchie H, Ortiz-Ospina E, Beltekian DJS, Research. Coronavirus(COVID-19) vaccinations–statistics and research.Our World in Data. 2021. Available from: https://ourworldindata.org/coronavirus

  4. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM.Trilogy of ACE2: A peptidase in the renin–angiotensinsystem, a SARS receptor, and a partner for amino acidtransporters. Pharmacol Ther. 2010;128(1):119-128.

  5. Soler MJ, Wysocki J, Batlle D. ACE2 alterations inkidney disease.Nephrol Dial Transplant. 2013;28(11):2687-2697.

  6. Lely A, Hamming I, H van Goor, Navis GJ. RenalACE2 expression in human kidney disease. JPathol. 2004;204(5):587-593.

  7. Ahmadian E, Hosseiniyan Khatibi SM, Razi SoofiyaniS, Abediazar S, Shoja MM, Ardalan M, et al. Covid‐19and kidney injury: Pathophysiology and molecularmechanisms. Rev Med Virol. 2021;31(3):e2176.

  8. Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu H-Y, etal. Renal histopathological analysis of 26 postmortemfindings of patients with COVID-19 in China. KidneyInt. 2020;98(1):219-227.

  9. Alwafi H, Ashoor D, Dairi M, Mokhtar G,Dairi K. Adult-Onset IgA Vasculitis Associatedwith Pulmonary-Renal Syndrome FollowingCOVID-19 Infection: A Case Report and LiteratureReview. Cureus. 2023;15(2).

  10. Waldman M, Sinaii N, Lerma EV, Kurien AA, JhaveriKD, Uppal NN, et al. COVID-19 Vaccination and newonset glomerular disease: Results from the IRocGN2International registry. Kidney360. 2023;4(3):349-362.

  11. Grassi S, Arena V, Zedda M, Cazzato F, Cianci R,Gambassi G, et al. What can autopsy say aboutCOVID-19? A case series of 60 autopsies. LegMed (Tokyo). 2023;62:102241.

  12. Eun JK, Park MJ, Kim MS, Han MH, Kim Y-J, BaekHS, et al. De Novo Crescentic GlomerulonephritisFollowing COVID-19 Infection: A Pediatric CaseReport. J Korean Med Sci. 2023;38(12): e89.

  13. Chandok T, Nasr R, Uday KA. A Case ofAntineutrophil Cytoplasmic Antibody Vasculitis-Associated Acute Kidney Injury in a Patient WithAsymptomatic COVID-19 Infection. Cureus.2023;15(2):e35006.

  14. Gulumsek E, Ozturk DD, Ozturk HA, Saler T,Erdogan KE, Bashir AM, et al. Minimal ChangeNephrotic Syndrome with Acute Kidney Injury afterthe Administration of Pfizer-BioNTech COVID-19Vaccine. Case Rep Infect Dis. 2023; 2023:1-4.

  15. De las Mercedes Noriega M, Husain-Syed F, WulfS, Csala B, Krebs CF, Jabs WJ, et al. Kidney BiopsyFindings in Patients with SARS-CoV-2 Infection orAfter COVID-19 Vaccination. Clin J Am Soc Nephrol.2023;15(5):612-625.

  16. Mateus C, Manso RT, Martins AR, Branco PQ.Membranous nephropathy after a recent SARS-CoV-2infection. BMJ Case Rep. 2023;16(1): e252468.

  17. Chen Y-S, Yang C-W, Tsai C-C, Ang M-D,Chou S-F, Chiang W-C, et al. Newly-diagnosedimmunoglobulin A nephropathy with increasedplasma galactose-deficient-IgA1 antibody associatedwith mRNA COVID-19 vaccination: a case report. JInt Med Res. 2022;50(10):03000605221129674.

  18. Tan MSH, Choo JCJ, Tan PH, Kwek JL, Lim CC,Mok IY, et al. Anti-glomerular basement membraneglomerulonephritis following COVID-19 infectionwithout clinically evident pneumonia. Int UrolNephrol. 2023;55(7):1-3.

  19. Özkan G, Bayrakçı N, Karabağ S, Güzel EÇ, UlusoyS, Nephrology. Relapse of minimal change disease afterinactivated SARS-CoV-2 vaccination: case report. IntUrol Nephrol. 2021;54(4):971-972.

  20. Hakroush S, Tampe D, Korsten P, Tampe B. Impact ofthe COVID-19 pandemic on kidney diseases requiringrenal biopsy: a single center observational study. FrontPhysiol. 2021;12:649336.

  21. Molnár A, Thomas MJ, Fintha A, Kardos M, DobiD, Tislér A, et al. Kidney biopsy-based epidemiologicanalysis shows a growing biopsy rate among theelderly. Sci Rep. 2021;11(1):24479.

  22. Bobart SA, Portalatin G, Sawaf H, Shettigar S, Carrion-Rodriguez A, Liang H, et al. The Cleveland ClinicKidney Biopsy Epidemiological Project. Kidney360.2022 Oct 18;3(12):2077-2085.

  23. Goh KL, Abeyaratne A, Ullah S, Rissel C,Priyadarshana K. Histopathology pattern and survivalanalysis of patients with kidney biopsy in the topend of Northern Australia from 2007 to 2020. BMCNephrol. 2022;23(1):385.

  24. Hu R, Quan S, Wang Y, Zhou Y, Zhang Y, Liu L,et al. The spectrum of biopsy-proven renal diseases inCentral China: a 10-year retrospective study based on34,630 cases. Sci Rep. 2020;10(1):1-12.

  25. Yim T, Kim S-U, Park S, Lim J-H, Jung H-Y, ChoJ-H, et al. Patterns in renal diseases diagnosed bykidney biopsy: a single-center experience. Kidney ResClin Pract. 2020;39(1):60.

  26. Muthu V, Ramachandran R, Nada R, Kumar V,Rathi M, Kohli H, et al. Clinicopathological spectrumof glomerular diseases in adolescents: A single-centerexperience over 4 Years. Indian J Nephrol. 2018;28(1):15.

  27. Chandra A, Rao N, Malhotra KP, Srivastava D,Nephrology. Impact of COVID-19 pandemic onpatients requiring renal biopsy. Int Urol Nephrol.2022;54(10):2617-2623.

  28. Bhalla S, Ahmad M, Raghuvanshi S, AgarwalP.Clinicopathologic spectrum of glomerular diseases ina tertiary care hospital. Indian Journal of Health Sciencesand Biomedical Research (KLEU). 2021;14(1):113-118.

  29. Al-Aly Z, Xie Y, Bowe B. High-dimensionalcharacterization of post-acute sequelae ofCOVID-19. Nature. 2021;594(7862):259-264.

  30. Nalbandian A, Sehgal K, Gupta A, Madhavan MV,McGroder C, Stevens JS, et al. Post-acute COVID-19syndrome. Nat Med. 2021;27(4):601-615.

  31. Norlander AE, Madhur MS, Harrison DG.The immunology of hypertension. J ExpMed. 2018;215(1):21-33.

  32. Vicenzi M, Di Cosola R, Ruscica M, Ratti A, RotaI, Rota F, et al. The liaison between respiratory failureand high blood pressure: evidence from COVID-19patients. Eur Respir J. 2020;56(1) :2001157.

  33. Chen G, Li X, Gong Z, Xia H, Wang Y, Wang X,et al. Hypertension as a sequela in patients of SARSCoV-2 infection. PLoS One. 2021;16(4):e0250815.

  34. Akpek M. Does COVID-19 causehypertension? Angiology. 2022;73(7):682-687.

  35. Angeli F, Zappa M, Oliva FM, Spanevello A,Verdecchia P. Blood pressure increase duringhospitalization for COVID-19. Eur J Intern Med.2022;104:110-112.




2020     |     www.medigraphic.com